Abstract
Considerable effort has been made to develop drugs that delay or prevent neurodegeneration. These include inhibitors of Aβ-generating proteases for the treatment of Alzheimers disease. Testing the amyloid hypothesis in vivo requires molecules that are capable of entering the CNS and that produce a substantial reduction in brain Aβ levels. Plaque-developing APP transgenic mice are currently widely used as an in vivo model of choice as these animals produce readily measurable amounts of human Aβ. They are very useful in the testing of a variety of amyloid-lowering approaches but their use for compound screening is often limited by their cost. Transgenic animals also require extensive, timeconsuming breeding programs and can show high inter-animal differences in the expression level of the transgene. Hence, we considered it important to develop and characterize a new and simple non-transgenic animal model for testing Aβ modulation. For this purpose, Wild-type adult Sprague Dawley rats were treated with DAPT, a functional γ-secretase inhibitor, and the Aβ40 and Aβ42 levels in brain-tissue and body fluids were assessed. We showed that DAPT, given orally, significantly lowered Aβ40 and Aβ42 peptide levels in brain extract, CSF, and the plasma dose- and timedependently. We can conclude that our data establish the usefulness of the wild-type rat model for testing small-molecule inhibitors of Aβ production.
Keywords: BACE1 inhibitors, ELISA, Monoclonal antibody, presenilin 1 (PS1), APP transgenic mice
Current Pharmaceutical Design
Title: Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Volume: 12 Issue: 6
Author(s): Mohammed El Mouedden, Marc Vandermeeren, Theo Meert and Marc Mercken
Affiliation:
Keywords: BACE1 inhibitors, ELISA, Monoclonal antibody, presenilin 1 (PS1), APP transgenic mice
Abstract: Considerable effort has been made to develop drugs that delay or prevent neurodegeneration. These include inhibitors of Aβ-generating proteases for the treatment of Alzheimers disease. Testing the amyloid hypothesis in vivo requires molecules that are capable of entering the CNS and that produce a substantial reduction in brain Aβ levels. Plaque-developing APP transgenic mice are currently widely used as an in vivo model of choice as these animals produce readily measurable amounts of human Aβ. They are very useful in the testing of a variety of amyloid-lowering approaches but their use for compound screening is often limited by their cost. Transgenic animals also require extensive, timeconsuming breeding programs and can show high inter-animal differences in the expression level of the transgene. Hence, we considered it important to develop and characterize a new and simple non-transgenic animal model for testing Aβ modulation. For this purpose, Wild-type adult Sprague Dawley rats were treated with DAPT, a functional γ-secretase inhibitor, and the Aβ40 and Aβ42 levels in brain-tissue and body fluids were assessed. We showed that DAPT, given orally, significantly lowered Aβ40 and Aβ42 peptide levels in brain extract, CSF, and the plasma dose- and timedependently. We can conclude that our data establish the usefulness of the wild-type rat model for testing small-molecule inhibitors of Aβ production.
Export Options
About this article
Cite this article as:
Mouedden El Mohammed, Vandermeeren Marc, Meert Theo and Mercken Marc, Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors, Current Pharmaceutical Design 2006; 12 (6) . https://dx.doi.org/10.2174/138161206775474233
DOI https://dx.doi.org/10.2174/138161206775474233 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry The Effect of <i>Stachy sieboldii</i> MIQ. Supplementation on Modulating Gut Microflora and Cytokine Expression in Mice
Combinatorial Chemistry & High Throughput Screening Vascular Patency: A Biomarker and Clinical Target Quantified with High Resolution MRI and Novel Cellular Pathways
Current Neurovascular Research Fermented Foods: Patented Approaches and Formulations for Nutritional Supplementation and Health Promotion
Recent Patents on Food, Nutrition & Agriculture miR-132 Down-regulates Methyl CpG Binding Protein 2 (MeCP2) During Cognitive Dysfunction Following Chronic Cerebral Hypoperfusion
Current Neurovascular Research Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Biocatalysis in the Preparation of the Statin Side Chain
Current Organic Synthesis Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Development of a Triggered Nocturnal Blood Pressure Monitoring which Detects Nighttime Blood Pressure Surges in Sleep Apnea Syndrome
Current Hypertension Reviews Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD)
Current Alzheimer Research Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer’s Disease
Current Alzheimer Research Editorial [Hot Topic:Perspective on Mild Cognitive Impairment (MCI) (Guest Editor: Bernardino Ghetti)]
Current Alzheimer Research Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design Hormonal Control of the Neuropeptide Y System
Current Protein & Peptide Science Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Kidney Dysfunction is Associated with a High Burden of Cerebral Small Vessel Disease in Primary Intracerebral Hemorrhage
Current Neurovascular Research An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews Complex Interactions between Phytochemicals. The Multi-Target Therapeutic Concept of Phytotherapy
Current Drug Targets